Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action

Journal of Neurochemistry

Volumn 91, Issue 3, 2004, Pages 521-536

  Gasparini, Laura ^a,b   Ongini, Ennio ^a   Wenk, Gary ^c  

^a Nicox Research Institute   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

amyloid; secretase; Alzheimer's disease; Cyclooxygenase; Non steroidal anti inflammatory drugs; Peroxisome proliferator activated receptor

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CONGO RED; DAPSONE; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENBUFEN; FENOPROFEN; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; NAPROXEN; NCX 2216; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; ROFECOXIB; SC 125; SULINDAC; SULINDAC SULFIDE; SUPROFEN; THIOFLAVINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CELL ACTIVATION; CELL CULTURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG USE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY CELL; MICROGLIA; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; REVIEW; RISK REDUCTION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; NEURONS; NEUROPROTECTIVE AGENTS; PPAR GAMMA;

MUS MUSCULUS;

EID: 7244226629     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02743.x     Document Type: Review

References (142)

1. 18F]fluoroethyl)(methyl)amino]-2-naphtyl} fcethylidene) malono nitrite. Neuroscience 117, 723-730.
2. Aisen P., Schafer K. A., Grundman M., Pfeiffer E., Sano M., Davis K. L., Farlow M. R., Jin S., Thomas R. G., Thal L. J. for the Alzheimer's Disease Cooperative Study (2003) Effects of rofecoxib or naproxen vs. placebo on Alzheimer Disease progression. JAMA 289, 2819-2826.
3. Asanuma M., Nishibayashi-Asanuma S., Miyazaki I., Kohno M. and Ogawa N. (2001) Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem. 76, 1895-1904.
4. Avramovich Y., Amit T. and Youdim M. B. H. (2002) Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 277, 31 466-31 473.
5. Bannwarth B., Netter P., Pourel J., Royer R. J. and Gaucher A. (1989) Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid. Biomed. Pharmacother. 43, 121-126.
6. Bannwarth B., Lapicque F., Pehourcq F., Gillet P., Schaeverbeke T., Laborde C., Dehais J., Gaucher A. and Netter P. (1995) Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid. Br. J. Clin. Pharmacol. 40, 266-269.
7. Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
8. Bazan N. G. (2001) COX-2 as a multifunctional neuronal modulator. Nature 7, 414-415.
9. Beher D., Clarke E. E., Wrigley J. D. J., Martin A. C. L., Nadin A., Churcher I. and Shearman M. S. (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. doi: 10.1074/jbc.M404937200.
10. Bertrand V., Guimbaud R., Sogni P., Lamrani A., Mauprivez C., Giroud J.-P., Couturier D., Chauvelot-Moachon L. and Chaussade S. (1998) Role of tumor necrosis factor-α and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity. Eur. J. Pharmacol. 356, 245-253.
11. Blasko I., Apochal A., Boeck G., Hartmann T., Grubeck-Loebenstein B. and Ransmayr G. (2001) Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol Dis. 8, 1094-1101.
12. Brune K. and Neubert A. (2001) Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin. Exp. Rheumatol. 19, S51-S57.
13. Candelario-Jalil E., Alvarez D., Gonzalez-Falcon A., Garcia-Cabrera M., Martinez-Sanchez G., Merino N., Giuliani A. and Leon O. S. (2002) Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia. Eur. J. Pharmacol. 453, 189-195.
14. Carro E., Trejo J. L., Gomez-Isla T., LeRoith D. and Torres-Aleman I. (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8, 1390-1397.
15. Chandrasekaran N. V., Dai H., Lamar Turepu Roos K., Evanson N. K., Tomsik J., Elton T. S. and Simmons D. L. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc. Natl Acad. Sci. USA 99, 13 926-13 931.
16. Chen H., Zhang S. M., Hernan M. A., Schwarzschild M. A., Willett W. C., Colditz G. A., Speizer F. E. and Ascherio A. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson Disease. Arch. Neurol. 60, 1059-1064.
17. Citron M. (2002) Alzheimer's disease: treatments in discovery and development. Nat. Neurosci. 5, 1055-1057.
18. Combs C. K., Johnson D. E., Colleen Kario J., Cannady S. B. and Landreth G. E. (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J. Neurosci. 20, 558-567.
19. Cryer B. and Feldman M. (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104, 413-421.
20. Cui J.-G., Kuroda H., Chandrasekharan N. V., Palacios Pelaez R., Simmons D. L., Bazan N. G. and Lukiw W. J. (2004) Cyclooxygenase-3 gene expression in the Alzheimer hippocampus and in stressed human cells. Neurochem. Res. in press.
21. Dedeoglu A., Choi J., Cormier K., Matson S. A., Ferrante R. J., Jenkins B. G. and Kowall N. W. (2003) Ibuprofen reduces Aβ (1-42)/Aβ (1-40) ratio in Alzheimer mice cortex at ages where no metabolic changes are noted by magnetic resonance spectroscopy. 2003 Abstract Viewer/Itinerary Planner, Program No. 203.9. Society for Neuroscience, Washington, DC. Online.
22. De Felice G. G. and Ferreira S. T. (2002) Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol. Neurobiol. 22, 545-563.
23. Dubois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B. A. and Lipsky P. E. (1998) Cyclooxygenase in biology and disease. FASEB J. 12, 1063-1073.
24. Eikelenboom P., Bate C., Van Gool W. A., Hoozemans J. J. M., Rozemulter J. M., Veerhuis R. and Williams A. (2002) Neuroinflammation in Alzheimer's disease and prion disease. Glia 40, 232-239.
25. Ekdahl C. T., Claasen J.-H., Bonde S., Kokaia Z. and Lindvall O. (2003) Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl Acad. Sci. USA 100, 13 632-13 637.
26. El-Agnaf O. M., Mahil D. S., Patel B. P. and Austen B. M. (2000) Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 273, 1003-1007.
27. El Khoury J., Hickman S. E., Thomas C. A., Cao L., Silverstein S. C. and Loike J. D. (1996) Scavenger receptor mediated adhesion of microglia to beta-amyloid fibrils. Nature 382, 716-719.
28. Engelhardt G., Bogel R., Scnitzer Chr and Utzmann R. (1996) Meloxicam: influence on arachidonic acid metabolism: Part 1. In vitro findings. Biochem. Pharmacol. 51, 21-28.
29. Eriksen J. L., Sagi S. A., Smith T. E. et al. (2003a) NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112, 440-449.
30. Eriksen J. L., Nicolle M. M., Prescott S. et al. (2003b) Chronic treatment of transgenic APP mice with R-flurbiprofen. 2003 Abstract Viewer/Itinerary Planner, Program No. 295.22. Society for Neuroscience, Washington, DC. Online.
31. Etminan M., Gill S. and Samii A. (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Br. Med. J. 327, 128-132.
32. Fici G. J., Himes C. S., Nye J. S., Merchant K. M. and Arneric S. P. (2003) Effects of NSAIDs and γ-secretase inhibitor on Aβ generation in guinea pig primary neuron cultures. 2003 Abstract Viewer/Itinerary Planner, Program No. 295.21. Society for Neuroscience, Washington, DC. Online.
33. Flower R. J. (2003) The development of COX-2 inhibitors. Nat. Drug Disc. Rev. 2, 179-191.
34. Frolich J. C. (1997) A classification of NSAIDs according to the relative inhibition of the cyclooxygenase enzymes. Trends Pharmacol. Sci. 18, 30-34.
35. Gala M., Sun R. and Yang V. W. (2002) Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways. Cancer Lett. 175, 89-94.
36. Gao H. M., Liu B., Zhang W. and Hong J.-S. (2003) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24, 395-401.
37. Gasparini L., Rusconi L., Xu H., del Soldato P. and Ongini E. (2004) Modulation of β-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cells. J. Neurochem. 88, 337-348.
38. Glenner G. G. and Wong C. W. (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131-1135.
39. Gouras G. K., Xu H., Jovanovic J. N., Buxbaum J. D., Wang R., Greengard P., Relkin N. R. and Gandy S. (1998) Generation and regulation of beta-amyloid peptide variants by neurons. J. Neurochem. 71, 1920-1925.
40. Graham S. H. and Hickey R. W. (2003) Cyclooxygenases in central nervous system diseases. A special role for cyclooxygenase 2 in neuronal death. Arch. Neurol. 60, 628-630.
41. Greenfield J. P., Gross R. S., Gouras G. K. and Xu H. (2000) Cellular and molecular basis of beta-amyloid precursor protein metabolism. Front. Biosci. 1, D72-D83.
42. Grilli M., Pizzi M., Memo M. and Spano P. (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 274, 1383-1385.
43. Halliday G. M., Shepherd C. E., NcCam H., Reid W. G. J., Grayson D. A., Broe A. and Kril J. J. (2000) Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch. Neurol. 57, 831-836.
44. Harkany T., Abraham I., Konya C., Nyakas C., Zarandi M., Penke B. and Luiten P. G. (2000) Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev. Neurosci. 11, 329-382.
45. Hauss-Wegrzyniak B., Dobrzanski P., Stoehr J. D. and Wenk G. L. (1998) Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 780, 294-303.
46. Hauss-Wegrzyniak B., Vraniak P. and Wenk G. L. (1999a) The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol. Aging 20, 305-313.
47. Hauss-Wegrzyniak B., Willard L. B., Del Soldato P., Pepeu G. and Wenk G. L. (1999b) Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res. 815, 36-43.
48. Hauss-Wegrzyniak B., Galons J. P. and Wenk G. L. (2000) Quantitative volumetric analysis of brain magnetic resonance imaging from rat with chronic neuroinflammation and correlation with histology. Exp. Neurol. 16, 347-354.
49. Hauss-Wegrzyniak B., Lynch M. A., Vraniak P. D. and Wenk G. L. (2002) Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path granule cell synapses. Exp. Neurol. 176, 336-341.
50. Herrmann C., Block C., Geisen C., Haas K., Weber C., Winde G., Möröy T. and Müller O. (1998) Sulindac sulfide inhibits Ras signaling. Oncogene 17, 1769-1776.
51. Ho L., Pieroni C., Ginger D., Purohit D. P., Aisen P. S. and Pasinetti G. M. (1999) Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res. 57, 295-303.
52. Ho L., Purohit D., Haroutunian V., Luterman J. D., Willis F., Naslund J., Buxbaum J. D., Mohs R. C., Aisen P. S. and Pasinetti G. M. (2001) Neuronal cyclooxygenase-2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer's disease. Arch. Neurol. 58, 487-492.
53. In't Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C., Stijnen T., Breteler M. M. B. and Stricker B. H. C. (2001) Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease. New Engl. J. Med. 21, 1515-1521.
54. In't Veld B. A., Launer L. J., Breteler M. M. B., Hofman A. and Stricker B. H. Ch (2002) Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiologic Rev. 24, 248-268.
55. Janciauskiene S., Sun J.-X. and Wright H. T. (2002) Interactions of Aβ with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer's disease. Neurobiol. Dis. 10, 187-200.
56. Jantzen P. T., Connor K. E., Di Carlo G., Wenk G. L., Wallace J. L., Rojiani A. M., Coppola D., Morgan D. G. and Gordon M. N. (2002) Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 2246-2254.
57. Jaradat M. S., Wongsud B., Phorchirasilp S., Rangwala S. M., Shams G., Sutton M., Romstedt K. J., Noonan D. J. and Feller D. R. (2001) Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin. Biochem. Pharmacol. 62, 1587-1595.
58. Jiang C., Ting A. T. and Seed B. (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
59. Kalgutkar A. S., Crews B. C., Rowlinson S. W., Marnett A. B., Kozak K. R., Remmel R. P. and Marnett L. J. (2000) Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl Acad. Sci. USA 97, 925-930.
60. Kawahara M. and Kuroda J. (2000) Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Res. Bull. 53, 389-397.
61. Kinouchi Y., Ono Y., Sorimachi H., Ishiura S. and Suzuki K. (1995) Arachidonate metabolites affect the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein. Biochem. Biophys. Res. Commun. 209, 841-849.
62. Kis B., Snipes J. A., Isse T., Nagy K. and Busija D. W. (2003) Putative cyclooxygenase-3 expression in rat brain cells. J. Cereb. Blood Flow Metabol. 23, 1287-1292.
63. Kitamura Y., Shimohama S., Koike H., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P. J. and Taniguchi T. (1999) Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-γ in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254, 582-586.
64. Klegeris A., Walker D. G. and McGeer P. L. (1999) Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology 38, 1017-1025.
65. Landreth G. E. and Heneka M. T. (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor γ agonists in Alzheimer's disease. Neurobiol. Aging 22, 937-944.
66. Lanz T. A., Wu H., Landrum C. S., Ellerbrock B. R., Nye J. S. and Merchant K. M. (2003) Reduced Aβ levels in tg2576 brain, CSF and plasma by potent γ-secretase inhibitors, but not by NSAIDs. 2003 Abstract Viewer/Itinerary Planner, Program No. 729.1. Society for Neuroscience, Washington, DC. Online.
67. 1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl] -L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309, 49-55.
68. Lee V. M. and Trojanowski J. Q. (1992) The disordered neuronal cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 2, 653-656.
69. Lee R. and Wurtman R. J. (2000) Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. Ann. NY Acad. Sci. 920, 261-268.
70. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M. and Kliewer S. A. (1997) Peroxisome proliferators-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410.
71. Lim G. P., Yang F., Chen P., Beech W., Teter B., Tran T., Ubeda O., Hsiao-Ashe K., Frautschy S. A. and Cole G. M. (1999) Ibuprofen suppresses plaque pathology in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
72. Lim G. P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., Overmier J. B., Hsiao-Ashe K., Frautschy S. A. and Cole G. M. (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983-991.
73. Lukiw W. J. and Bazan N. G. (1997) Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 50, 937-945.
74. Mackenzie I. R. A. and Munoz D. (1998) Non-steroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50, 986-990.
75. Marambaud P., Chevallier N., Ancolio P. and Checler F. (1998) Post-transcriptional contribution of a cAMP-dependent pathway to the formation of α- and β/γ-secretase-derived products of βAPP maturation in human cells expressing wild-type and Swedish mutated βAPP. Mol. Med. 4, 715-723.
76. Matoga M., Pehourcq F., Lagrange F., Tramu G. and Bannwarth B. (1999) Influence of molecular lipophilicity on the diffusion of arylpropionate non-steroidal anti-inflammatory drugs into the cerebrospinal fluid. Arzneim.-Forsch./Drug Res. 49, 477-482.
77. Matsuoka Y., Picciano M., Malester B. et al. (2001) Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158, 1345-1354.
78. Mazur-Kolecka B., Frackowiak J. and Wisniewski H. M. (1995) Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's beta-amyloid peptide in cultured vascular smooth muscle cells. Brain Res. 698, 217-222.
79. McGeer P. L. and McGeer E. G. (2001) Polymorphisms in inflammatory genes and the risk of Alzheimer Disease. Arch. Neurol. 58, 1790-1792.
80. McGeer E. G. and McGeer P. L. (2003) Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatr. 27, 741-749.
81. Merched A., Serot J. M., Visvikis S., Aguillon D., Faure G. and Siest G. (1998) Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett. 425, 225-228.
82. Moechars D., Dewachter I., Lorent K. et al. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492.
83. Monje M. L., Toda H. and Palmer T. D. (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760-1765.
84. Montine T. J., Sidell K. R., Crews B. C., Markersbery W. R., Marnett L. J., Roberts L. J. 2nd and Morrow J. D. (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495-1498.
85. Morihara T., Chu T., Ubeda O., Beech W. and Cole G. M. (2002) Selective inhibition of Aβ42 production by NSAID R-enantiomers. J. Neurochem. 83, 1009-1012.
86. Netland E. E., Newton J. L., Majocha R. E. and Tate B. A. (1998) Indomethacin reverses the microglial response to amyloid-β-protein. Neurobiol. Aging 19, 201-204.
87. The Neuroinflammation Working Group (2000) Inflammation and Alzheimer's Disease. Neurobiol. Aging 21, 383-421.
88. Nie W. and Goldgaber D. (2003) Effect of NSAIDs and cytokines on transthyretin (TTR) secreted by human hepatoblastoma (Hepg2) cells. 2003 (Abstract) Viewer/Itinerary Planner, Program No. 20.1. Society for Neuroscience, Washington, DC. Online.
89. Palha J. A., Moreira P., Wisniewski T., Frangione B. and Saraiva M. J. (1996) Transthyretin gene in Alzheimer's disease patients. Neurosci. Lett. 204, 212-214.
90. Pang L., Nie M., Corbett L. and Knox A. J. (2003) Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airways smooth muscle cells: role of peroxisome proliferator-activated receptors. J. Immunol. 170, 1043-1051.
91. Paresce D. M., Ghosh R. N. and Maxfield F. R. (1996) Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron 17, 553-565.
92. Patrono C., Patrignani P. and Rodriguez L. A. G. (2001) Cyclooxygenase-selective inhibition of prostanoid formation transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 108, 7-13.
93. Pehrourcq F., Matoga M. and Bannwarth B. (2004) Diffusion of arylpropionate non-steroidal anti-inflammatory drugs into the cerebrospinal fluid: a quantitative structure-activity relationship approach. Fundamental Clin. Pharmacol. 18, 65-70.
94. Podlisny M. B., Walsh D. M., Amarante P., Ostaszewski B. L., Stimson E. R., Maggio J. E., Teplow D. B. and Selkoe D. J. (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by congo red. Biochemistry 37, 3602-3611.
95. Praticò D., Yao Y., Uryu K., Yang H., Trojanowsi J. Q. and Lee V.-M. Y. (2003) Opposite effects of indomethacin and nimesulide on levels and amyloid deposition in a transgenic mouse model of Alzheimer amyloidosis. 2003 Abstract Viewer/Itinerary Planner, Program No. 20.4. Society for Neuroscience, Washington, DC. Online.
96. Prosperi C., Scali C., Pepeu G. and Casamenti F. (2001) NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain. Jpn. J. Pharmacol. 86, 230-235.
97. Prosperi C., Scali C., Barba M., Bellucci A., Giovannini M., Pepeu G. and Casamenti F. (2004) Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT1026 and NCX2216 on Aβ(1-42)-induced brain inflammation and neuronal damage in the rat. Int. J. Immunol. Pharmacol. in press.
98. Quinn J., Montine T., Morrow J., Woodward W. R., Kulhanek D. and Eckenstein F. (2003) Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol. 137, 32-41.
99. Ray I., Chauhan A., Wisniewski H. M., Wegiel J., Kim K. S. and Chauhan V. P. (1998) Binding of amyloid β-protein to intracellular brain proteins in rat and human. Neurochem. Res. 23, 1277-1282.
100. Reid G., Wielinga P., Zelcel N., van der Heijden I., Kuil A., de Haas M., Wijinholds J. and Borst P. (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc. Natl Acad. Sci. USA 100, 9244-9249.
101. Reilly I. A. and FitzGerald G. A. (1987) Inhibition of tromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69, 180-186.
102. Reines S. A., Block G. A., Morris J. C., Liu G., Nessly M. L., Lines C. R., Norman B. A., Baranak C. C. and Rofecoxib Protocol 091 Study Group (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66-71.
103. Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferators-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82.
104. Rüsoen H. (1988) Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol. Scand. 78, 455-459.
105. Rosi S., McGann K., Hauss-Wegrzyniak B. and Wenk G. L. (2003) The influence of brain inflammation upon neuronal adenosine A2B receptors. J. Neurochem. 86, 220-227.
106. Sagi S. A., Weggen S., Eriksen J., Golde T. E. and Koo E. H. (2003a) The non-COX targets of NSAIDs, lipooxygenases, PPARs, IKK, and NFκB, do not reduce Aβ42 production. J. Biol. Chem. 278, 31 825-31 830.
107. Sagi S. A., Eriksen J. L., Beard J., Ozols V., Weggen S., Smith T. E., Koo E. H. and Golde T. E. (2003b) Aβ42 lowering NSAIDs can be converted into Aβ42 raising agents by simple structural modifications. 2003 Abstract Viewer/Itinerary Planner, Program No. 876.14. Society for Neuroscience, Washington, DC. Online.
108. Sastre M., Dewatcher I., Landreth G. E., Willson T. M., Klockgether T., van Leuven F. and Heneka M. T. (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J. Neurosci. 23, 9796-9804.
109. Scali C., Prosperi C., Vannucchi M. G., Pepeu G. and Casamenti F. (2000) Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. Eur. J. Neurosci. 12, 1900-1912.
110. Scali C., Giovannini M. G., Prosperi C., Bellocci A., Pepeu G. and Casamenti F. (2003) The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 117, 909-919.
111. Schwab J. M. and Schluesener H. J. (2003) Cyclooxygenases and central nervous system inflammation. Conceptual neglet of cyclooxygenase 1. Arch. Neurol. 60, 630-632.
112. Schwarzman A. L., Gregori L., Vitek M. P. et al. (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc. Natl Acad. Sci. USA 91, 8368-8372.
113. Shen Y. and Meri S. (2003) Ying and yang: complement activation and regulation in Alzheimer's disease. Prog. Neurobiol. 70, 463-472.
114. Shen Y., Lue L. F., Yang L.-B. et al. (2001) Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 305, 165-168.
115. Skovronsky D. M., Lee W. M. Y. and Pratico D. (2001) Amyloid precursor protein and amyloid β-peptide in human platelets. Role of cyclooxygenase and protein kinase C. J. Biol. Chem. 278, 17 036-17 043.
116. Stewart W. F., Kawas C., Corrada M. and Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
117. Takahashi Y., Hayashi I., Tominari Y., Rikimaru K., Morohashi Y., Kan T., Natsugari H., Fukuyama T., Tomita T. and Iwatsubo T. (2003) Sulindac sulphide is a noncompetitive γ-secretase inhibitor that preferentially reduces Aβ42 generation. J. Biol. Chem. 278, 18 664-18 670.
118. Talaga P. (2001) Beta-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality? Mini Rev. Med. Chem. 1, 175-186.
119. Tegeder I., Pfeilschifter J. and Geisslinger G. (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15, 2057-2072.
120. Thomas T., Nadackal G. T. and Thomas K. (2001) Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-β aggregation. Neuropharmacol. Neurotoxicol. 12, 3263-3267.
121. Vane J. R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232-235.
122. Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
123. Wallace J. L., Muscara M. N., de Nucci G., Zamuner S., Cirino G., del Soldato P. and Ongini E. (2004) Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative (NCX 2216, [3-[4-(2-fluoro-α-methyl-[1,1-biphenyl]-4-acetyloxy)-3- methoxyphenyl]-2-propenoic acid 4-nitrooxybutyl ester]. J. Pharmacol Exp. Ther. 309, 626-633.
124. Warner T. D. and Mitchell J. A. (2003) Nonsteroidal anti-inflammatory drugs inhibiting prostanoid efflux: as easy as ABC? Proc. Natl Acad. Sci. USA 100, 9108-9110.
125. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216.
126. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Ozols V., Fauq A., Golde T. E. and Koo E. H. (2003a) Evidence that nonsteroidal anti-inflammatory drugs decrease Aβ42 production by direct modulation of γ-secretase activity. J. Biol. Chem. 278, 31 831-31 837.
127. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Golde T. E. and Koo E. H. (2003b) Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. 278, 30 748-30 754.
128. Wenk G. L., McGann K., Mencarelli A., Hauss-Wegrzyniak B., del Soldato P. and Fiorucci S. (2000) Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur. J. Pharmacol. 402, 77-85.
129. Wenk G. L., McGann-Gramling K., Hauss-Wegrzyniak B., Maucci R., Ronchetti D., Rosi S., Gasparini L. and Ongini E. (2004) Attenuation of chronic neuroinflammation by nitric oxide-releasing derivative of the antioxidant ferulic acid. J. Neurochem. 89, 484-493.
130. Wick M., Hurteau G., Dessev C., Chan D., Geraci M. W., Winn R. A., Heasley L. E. and Nemenoff R. A. (2002) Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol. 62, 1207-1214.
131. Wilson C. A., Doms R. W., Zheng H. and Lee V. M.-Y. (2002) Presenilins are not required for Aβ42 production in the early secretory pathway. Nat. Neurosci. 5, 849-855.
132. Wrigley J. D. J., Martin A. C. L., Clarke E. E., Lewis H. D., Pollack S. J., Shearman M. S. and Beher D. (2003) Modulation versus inhibition-selected NSAIDs can act as γ-secretase inhibitors in vitro. 2003 Abstract Viewer/Itinerary Planner, Program No. 295.2. Society for Neuroscience, Washington, DC. Online.
133. Wyss-Coray T. and Mucke L. (2002) Inflammation in neurodegenerative disease - a double-edged sword. Neuron 35, 419-432.
134. Xiang Z., Ho L., Yemul S., Zhao Z., Qing W., Pompl P., Kelley K., Dang A., Qing W., Teplow D. and Pasinetti G. M. (2002a) Cyclooxygenase-2 promote amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 10, 271-278.
135. Xiang Z., Ho L., Valdellon J., Borchelt D., Kelley K., Spielman L., Aisen P. S. and Pasinetti G. M. (2002b) Cyclooxygenase (COX-2) and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging 23, 327-334.
136. Xu H., Sweeney D., Greengard P. and Gandy S. (1996) Metabolism of Alzheimer β-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Proc. Natl Acad. Sci. USA 93, 4081-4084.
137. Xu H., Gouras G. K., Greenfield J. P. et al. (1998) Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat. Med. 4, 447-451.
138. Yan S. D., Roher A., Schmidt A. M. and Stern D. M. (1999) Cellular cofactors for amyloid β-peptide-induced cell stress. Moving from cell cultures to in vivo. Am. J. Pathol 155, 1403-1411.
139. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A. L., Citron M. and Landreth G. (2003) Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509.
140. Yermakova A. V., Rollins J., Callahan L. M., Rogers J. and O'Banion M. K. (1999) Cyclooxygenase-1 in human Alzheimer's and control brain: quantitative analysis of expression by microglia, and CA3 hippocampal neurons. Exp. Neurol. 58, 1135-1146.
141. Yermakova A. V. and O'Banion M. K. (2001) Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging 22, 823-836.
142. Zhou Y., Su Y., Li B. et al. (2003) Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting rho. Science 302, 1215-1217.